drugset
drugset / Trial / NCT04791332

A Study of JNJ-67953964 in Healthy Japanese Adult Male Participants

NCT04791332 ↗

Phase 1 Completed 30 enrolled Janssen Pharmaceutical K.K.
RandomizedParallel-groupDouble-blindOther

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) after single- and multiple-dose oral administration of JNJ-67953964 in healthy Japanese adult male participants.

Timeline

Start
2021-04-30
Primary completion
2021-07-28
Completion
2021-07-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Aticaprant Small molecule — Oral

Indications

No indication recorded.